Oakworth Capital Inc. grew its stake in shares of Celgene Corporation (NASDAQ:CELG) by 11.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,216 shares of the biopharmaceutical company’s stock after acquiring an additional 127 shares during the period. Oakworth Capital Inc.’s holdings in Celgene Corporation were worth $158,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. State Street Corp grew its stake in Celgene Corporation by 2.3% in the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after acquiring an additional 723,844 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Celgene Corporation by 4.9% during the 1st quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock valued at $1,255,309,000 after acquiring an additional 472,067 shares in the last quarter. American Century Companies Inc. increased its holdings in Celgene Corporation by 4.4% during the 1st quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock valued at $816,733,000 after acquiring an additional 276,089 shares in the last quarter. Pioneer Investment Management Inc. increased its holdings in Celgene Corporation by 15.7% during the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after acquiring an additional 710,584 shares in the last quarter. Finally, Clearbridge Investments LLC increased its holdings in Celgene Corporation by 24.1% during the 1st quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after acquiring an additional 892,392 shares in the last quarter. Institutional investors own 79.36% of the company’s stock.

In related news, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the transaction, the director now directly owns 69,424 shares in the company, valued at approximately $9,061,220.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The disclosure for this sale can be found here. Insiders sold 46,233 shares of company stock valued at $6,268,259 over the last 90 days. 0.95% of the stock is owned by corporate insiders.

A number of equities analysts have issued reports on CELG shares. Stifel Nicolaus restated a “buy” rating and set a $139.00 target price on shares of Celgene Corporation in a research report on Thursday, July 6th. Cantor Fitzgerald set a $160.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 6th. Oppenheimer Holdings, Inc. set a $148.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, June 8th. Cann reissued a “buy” rating on shares of Celgene Corporation in a research note on Wednesday, June 7th. Finally, Canaccord Genuity set a $156.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Tuesday, June 6th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twenty have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $150.54.

Celgene Corporation (CELG) opened at 146.04 on Tuesday. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $147.17. The firm has a market capitalization of $114.25 billion, a price-to-earnings ratio of 45.23 and a beta of 1.89. The company’s 50-day moving average price is $137.92 and its 200 day moving average price is $129.09.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter last year, the company posted $1.44 earnings per share. The company’s revenue for the quarter was up 18.7% compared to the same quarter last year. Equities research analysts predict that Celgene Corporation will post $7.32 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Oakworth Capital Inc. Boosts Stake in Celgene Corporation (CELG)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/03/oakworth-capital-inc-boosts-stake-in-celgene-corporation-celg.html.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.